A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies
EudraCT / EU CT No
2024-516869-36-00
Protocol No
EXS73565-001
Trial information
Medical condition
CLL, DLBCL, MCL, MZL, WALDENSTROM, FL
Trial phase
Phase 1
Sponsor
Exscientia AI Ltd
Start date
17/06/2026
End date
Recruiting
Main objective
TEAEs, DLTs
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Patras
University Hospital of Patras
Alexandros Spyridonidis
+302613604169
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.
